EAU 2013 - Programme Book - YouMed

ESU Courses, 16 March
ESU Course 1
14.30 - 17.30 Prostate cancer – Screening, diagnosis and staging
Green Hall 1 - Level N-1
Screening
F.C. Hamdy, Oxford (GB)
Diagnosis
A.R. Zlotta, Toronto (CA)
Staging
A.R. Zlotta, Toronto (CA)
Chair: F.C. Hamdy, Oxford (GB)
Aims and objectives
The incidence of prostate cancer has increased dramatically over the last 10 to 15 years and it is now the
most common cancer in males in developed countries. The increase is mainly caused by the growing use
of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in
serum. Using this approach, prostate cancer is detected 5 to 10 years before giving rise to symptoms and on
average 17 years before causing the death of the patient. While this has led to detection of prostate cancer
at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that
would not surface clinically in the absence of screening. This is confounded by recent evidence that screening
reduces disease-specific mortality. A major challenge is thus to identify the cases that need to be treated
while avoiding diagnosing patients who will not benefit from being diagnosed and who will only suffer from
the stigma of being a cancer patient. Therefore, prognostic markers, which can predict those patients who
need to be diagnosed and those who do not, are of major importance. This course is designed for urological
trainees and established urologists, who wish to update themselves on the latest information regarding
screening, diagnosis and staging in prostate cancer. The course allows interaction with the audience and is
in part based on case-scenarios for discussion with the delegates, followed by state-of-the-art presentations.
In addition, emphasis will be placed on controversial issues and recent progress in terms of diagnostic tools,
staging procedures and prognostic factors. At the end of the course, the participants should have obtained
good insights on the following:
• What are the best approaches to screening and early detection of prostate?
• How can we reduce the risk of overdiagnosis and overtreatment?
• How can we identify patients who are best managed by active monitoring/surveillance rather than
immediate more active treatment?
Registration fee excluding VAT
EAU members € 47
Non-EAU members € 69
Residents (members/non-members) € 21
EAU Milan 2013
321
ESU Courses